NYSE: CC · Specialty Chemicals

Chemours (CC) fair value and price range

As of 14 Nov 2026, Faircurve's model values Chemours (CC) at $13.12 a share. The stock last closed at $12.48, which puts the model's fair value 5.1% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

Revalued . Price is the close of 16 Nov 2026. The Chemours Company.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$13.12midpoint of 2,000 simulations
Last close$12.48NYSE: CC
Gap to fair value+5.1%fair value against price
Model verdictLow evidence gradeevidence grade: Low

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $12.20 to $13.12 (+7.5%). The companies the model compares it with now trade on higher multiples: most of the move.

What the model makes of itThe price of $12.48 is 5.1% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What's nextNext report on 18 Feb 2027. Options prices imply a move of about 15% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give CC?

The calibrated range for CC over 63 trading days is $10.47 to $15.00. It sits around the last close, and its width comes from the volatility that CC's own options imply (53% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $2.54 to $27.52. In 50% of the simulations the fair value came out above the price the model ran on.

$0.75$59.29
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $13.12. Dashed line: the last close, $12.48.

Faircurve Insights · 14 Nov 2026

The Chemours Company (CC) provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America.

Faircurve's model put the fair value at $13.12 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $12.20, so the fair value moved +7.5%. The model's reason: "The companies the model compares it with now trade on higher multiples: most of the move." The calibrated range over 63 trading days is $10.47 to $15.00. It is built from the volatility the stock's own options imply and calibrated weekly against realised prices, using 8,038 past valuations refreshed on 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

The business scores 28 out of 100 on the model's overall quality score, measured against comparable companies. Its balance sheet scores 0, with net debt to EBITDA at 554.50x against a peer median of 4.17x. Profitability scores 15, with ROIC at -3.3% against a peer median of 6.1%. Growth quality scores 28, with trailing revenue growth at 0.4% against a peer median of 2.7%. The model compares it with Innospec Inc. (IOSP), Minerals Technologies Inc. (MTX), Stepan Co (SCL), H.B. Fuller Company (FUL), Quaker Houghton (KWR) and Hawkins, Inc. (HWKN).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does CC report earnings, and how has the stock reacted?

Chemours's next earnings report is scheduled for 18 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 8.1% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. CC's 30 day implied volatility works out to about 15.3% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CC's last 8 reports, ignoring direction, was 5.7%.

0%5%10%15%20%12.8%2.0%18 Feb '2514.9%1.7%5 Aug '2513.6%3.8%6 Nov '2513.9%19.4%19 Feb '2613.4%13.0%5 May '2615.3%14.7%4 Aug '2611.6%3.3%2 Nov '266.9%7.5%5 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in CC

10%15%20%25%30%5 Nov '26 report2 Nov '26 report4 Aug '26 report5 May '26 report19 Feb '26 report15% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 19% on 14 Nov 2025, reached 25% on 13 Feb 2026 and reads 15% on 16 Nov 2026. The marks are report dates.

How does CC score on business quality?

Chemours's overall quality score is 28 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.15-3.3%ROIC6.1%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).55
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.280.4%Revenue growth, trailing2.7%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.390.0%Net buybacks / market value1.6%
Balance sheetNet debt to EBITDA and interest coverage.0554.50xNet debt / EBITDA4.17x
StabilityDownside volatility of the EBITDA margin over the last five years.264.4 ptsEBITDA margin downside volatility, 5y3.0 pts

How does CC compare with similar companies?

The companies in specialty chemicals closest to Chemours in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
IOSP Innospec Inc.$79.17$79.13-0.1%Fairly valued
NGVT Ingevity Corporation$60.02$67.46+12.4%Low evidence grade
MTX Minerals Technologies Inc.$60.57$65.44+8.0%Fairly valued
SCL Stepan Co$66.90$61.52-8.0%Fairly valued
FUL H.B. Fuller Company$49.00$54.04+10.3%Fairly valued
KWR Quaker Houghton$152.07$131.10-13.8%Fairly valued
WDFC WD-40 Company$226.01$208.49-7.8%Low evidence grade
HWKN Hawkins, Inc.$148.66$136.46-8.2%Fairly valued

What the comparable companies' multiples alone would give for CC, the peer-implied price, is $12.27 a share on this run. The fair value weighs that against the company's own multiple.

All specialty chemical stocks ranked by gap to fair value

Chemours at a glance

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America.

Market value
$2.0B
Sector
Basic Materials
Industry
Specialty Chemicals
Revenue expected, next twelve months
$6.1B
Consensus revenue growth, next fiscal year
+2.1%
Analysts with estimates
5
Beta to the US market
1.37
First valued by Faircurve
11 Jul 2026

How the fair value is worked out: the model prices Chemours on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for CC was $12.20. As of 14 Nov 2026 it is $13.12, a change of +7.5%. The companies the model compares it with now trade on higher multiples: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Chemours's valuation

Is Chemours stock undervalued or overvalued?

Faircurve's model puts CC's fair value at $13.12 a share against a last close of $12.48, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What is CC's fair value?

$13.12 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $2.54 to $27.52.

What price range does the model give CC?

$10.47 to $15.00 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Chemours report earnings next?

The next report is scheduled for 18 Feb 2027. Companies can move their dates.

How much has CC moved on past earnings reports?

Across its last 8 reports the median two session move was 5.7%, ignoring direction. The largest was -19.4% around the report of 19 Feb 2026.

How confident is the model in this valuation?

The model's evidence grade for CC is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on CC

The model holds no idea open on CC today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CC with their outcomes. A free account is enough.

Keep reading